Datum Källa Rubrik Typ Alternativ
2024-04-30 Abliva Amended number of shares and votes in Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-04-30 Abliva Ändring av antal aktier och röster i Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-04-25 Abliva Abliva beslutar om en riktad emission av aktier till garanter i samband med den genomförda företrädesemissionen Pressreleaser Ladda ner | Visa Stäng
2024-04-25 Abliva Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue Pressreleaser Ladda ner | Visa Stäng
2024-04-24 Abliva Abliva AB publicerar årsredovisningen för 2023 Rapporter Ladda ner | Visa Stäng
2024-04-24 Abliva Abliva AB Publishes 2023 Annual Report Rapporter Ladda ner | Visa Stäng
2024-04-22 Abliva Kallelse till årsstämma i Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-04-22 Abliva Notice of Annual General Meeting of Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-04-19 Abliva Abliva publishes rights issue outcome Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 19 Apr 2024 | Abliva

Abliva publishes rights issue outcome

THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER COUNTRY WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN, IN ADDITION TO THE REQUIREMENTS UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva”) or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company on 22 February 2024 (the “Rights Issue”), has been completed. In the Rights Issue, 184,931,634 shares, corresponding to approximately 64.2 percent of the Rights Issue, were subscribed for with the use of subscription rights. In addition, 3,241,219 shares, corresponding to approximately 1.1 percent of the Rights Issue, were subscribed for without the use of subscription rights and 99,908,735 shares, corresponding to approximately 34.7 percent of the Rights Issue, were subscribed for by share issue guarantors. In total, the Rights Issue was subscribed to 100 percent, which implies that Abliva raises approximately SEK 46 million before deduction for transactions costs. The rights issue is part of an approximately SEK 88 million financing that also includes a directed issue of convertible bonds to a limited number of certain existing shareholders and institutional investors, provided that the result from the interim analysis, in mid-2024, is positive (non-futile).

Through the Rights Issue, Abliva raises approximately SEK 46 million before transactions costs, which are estimated to amount to approximately SEK 6.5 million. The final outcome shows that 184,931,634 shares, corresponding to approximately 64.2 percent of the Rights Issue, were subscribed for with the use of subscription rights. In addition, 3,241,219 shares, corresponding to approximately 1.1 percent of the Rights Issue, were subscribed for without the use of subscription rights and 99,908,735 shares, corresponding to approximately 34.7 percent of the Rights Issue, were subscribed for by share issue guarantors.

Through the Rights Issue, the Company’s share capital increases by SEK 14,404,079.40 from SEK 52,814,958.25 to SEK 67,219,037.65 and the number of shares increases by 288,081,588 shares from 1,056,299,165 shares to 1,344,380,753 shares.

Trading in paid subscribed shares (BTA) on Nasdaq Stockholm will continue under the short name ABLI BTA until the Rights Issue has been registered with the Swedish Companies Registration Office (Sv. Bolagsverket), which is expected to take place on or around May 8, 2024. After that, BTA will be converted into shares after approximately one week.

Allotment of shares subscribed for without the use of subscription rights has been made in accordance with the principles set out in the prospectus that has been prepared for the Rights Issue and published by the Company on 27 March 2024. Notice of allotment is provided through the distribution of a settlement note by mail to the respective subscriber. Allotted shares shall be paid for in accordance with the instructions on the settlement note.

I would like to take this opportunity to thank everyone who participated in the rights issue. Your participation ensures that we can continue our work in the KL1333 program while we carry out the interim analysis. In addition, this financing will allow us to prepare for the final stage of the FALCON study while providing additional runway to discuss the program with potential partners and investors”, said Ellen Donnelly, CEO of Abliva AB.

Holders of convertible bonds shall convert the entirety of the loan amount within five banking days from the time at which the Company announces the interim data from the KL1333 Phase 2 study, estimated in mid-2024, if it results in a positive, i.e. non futile, outcome.

Advisors
Hagberg & Aneborn Fondkommission AB is the sole global coordinator and bookrunner in connection with the Rights Issue. Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the Rights Issue.

2024-04-19 Abliva Abliva offentliggör utfall i företrädesemission Pressreleaser Ladda ner | Visa Stäng
2024-04-08 Abliva BioStock: Abliva vill bli en nyckelspelare inom mitokondriell medicin Pressreleaser Visa Stäng
2024-04-08 Abliva BioStock: Abliva's mission to become mitochondrial medicine powerhouse Pressreleaser Visa Stäng
2024-03-27 Abliva Abliva offentliggör prospekt med anledning av företrädesemission som till 100 procent omfattas av tecknings- och garantiåtaganden och upptagande till handel av nyemitterade aktier Pressreleaser Ladda ner | Visa Stäng
2024-03-27 Abliva Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares Pressreleaser Ladda ner | Visa Stäng
2024-03-26 Abliva Beslut vid extra bolagsstämma i Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-03-26 Abliva Resolutions at the Extraordinary General Meeting in Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-02-29 Abliva BioStock: Ablivas vd kommenterar den föreslagna kapitalanskaffningen Pressreleaser Visa Stäng
2024-02-29 Abliva BioStock: Abliva's CEO comments on the proposed capital raise Pressreleaser Visa Stäng
2024-02-27 Penser Future by Carnegie Penser Future by Carnegie: Abliva - Interimdata i sommar Pressreleaser Visa Stäng
2024-02-23 Abliva Abliva AB Year-End Report January – December 2023 Rapporter Ladda ner | Visa Stäng
2024-02-23 Abliva Abliva AB Bokslutskommuniké januari – december 2023 Rapporter Ladda ner | Visa Stäng
2024-02-22 Abliva Notice of Extraordinary General Meeting of Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-02-22 Abliva Kallelse till extra bolagsstämma i Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-02-22 Abliva Styrelsen för Abliva beslutar om en fullt garanterad företrädesemission om 46 MSEK och en riktad emission av konvertibler om 42 MSEK för att förbereda slutfasen av FALCON-studien med KL1333 Pressreleaser Ladda ner | Visa Stäng
2024-02-22 Abliva The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study Pressreleaser Ladda ner | Visa Stäng
2023-12-21 Abliva BioStock: Abliva reaches enrollment goal Pressreleaser Visa Stäng
2023-12-21 Abliva BioStock: Abliva når mål för patientinkludering Pressreleaser Visa Stäng
2023-12-20 Abliva Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study Pressreleaser Ladda ner | Visa Stäng
2023-12-20 Abliva Abliva når mål för patientinkludering i Steg 1 av FALCON-studien Pressreleaser Ladda ner | Visa Stäng
2023-12-15 Abliva BioStock: Ablivas vd: "Orphan drug designation is great validation" Pressreleaser Visa Stäng
2023-12-15 Abliva BioStock: Abliva's CEO: "Orphan drug designation is great validation" Pressreleaser Visa Stäng
2023-12-15 Penser Future by Carnegie Penser Future by Carnegie: Abliva - Huvudkonkurrent misslyckas Pressreleaser Visa Stäng
2023-12-14 Penser Future by Carnegie Penser Future by Carnegie: Abliva - 4 minutes by Penser Pressreleaser Visa Stäng
2023-12-14 Abliva Abliva erhåller särläkemedelsklassificering från EU-kommissionen för sin läkemedelskandidat NV354 Pressreleaser Ladda ner | Visa Stäng
2023-12-14 Abliva Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354 Pressreleaser Ladda ner | Visa Stäng
2023-11-20 Penser Future Penser Future: Luft under vingarna - Abliva Pressreleaser Visa Stäng
2023-11-17 Abliva Abliva AB Delårsrapport januari – september 2023 Rapporter Ladda ner | Visa Stäng
2023-11-17 Abliva Abliva AB Interim Report January – September 2023 Rapporter Ladda ner | Visa Stäng
2023-11-16 Abliva BioStock: Abliva signs global license deal for NeuroSTAT Pressreleaser Visa Stäng
2023-11-16 Abliva BioStock: Abliva tecknar globalt licensavtal för NeuroSTAT Pressreleaser Visa Stäng
2023-11-15 Penser Future Penser Future: Licensierar ut NeuroSTAT - Abliva Pressreleaser Visa Stäng
2023-11-14 Abliva Abliva och Owl Therapeutics ingår licens- och samarbetsavtal för NeuroSTAT® vid traumatisk hjärnskada Pressreleaser Ladda ner | Visa Stäng
2023-11-14 Abliva Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury Pressreleaser Ladda ner | Visa Stäng
2023-10-18 Abliva Abliva presenterar på BioStock Life Science Summit den 25 oktober Pressreleaser Visa Stäng
2023-10-18 Abliva BioStock: Abliva's VP of Clinical Operations on the screening achievement Pressreleaser Visa Stäng
2023-10-18 Abliva BioStock: Ablivas VP of Clinical Operations om uppnått screening-mål Pressreleaser Visa Stäng
2023-10-11 Abliva Abliva Achieves Important Milestone in the Ongoing FALCON Study Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Abliva Abliva når viktig milstolpe i den pågående FALCON-studien Pressreleaser Ladda ner | Visa Stäng
2023-09-19 Abliva BioStock:Abliva increases awareness of mitochondrial diseases Pressreleaser Visa Stäng
2023-09-19 Abliva BioStock:Abliva ökar medvetenheten om mitkondriella sjukdomar Pressreleaser Visa Stäng
2023-09-18 Abliva Abliva to Participate in World Mitochondrial Disease Week 2023 Pressreleaser Ladda ner | Visa Stäng
2023-09-18 Abliva Abliva uppmärksammar World Mitochondrial Disease Week 2023 Pressreleaser Ladda ner | Visa Stäng
2023-09-08 Abliva BioStock: Abliva erhåller FDA Fast Track-status Pressreleaser Visa Stäng
2023-09-08 Abliva BioStock: Abliva receives FDA Fast Track designation Pressreleaser Visa Stäng
2023-09-04 Abliva Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation Pressreleaser Ladda ner | Visa Stäng
2023-09-04 Abliva Ablivas huvudkandidat KL1333 får Fast Track-status från FDA Pressreleaser Ladda ner | Visa Stäng
2023-08-21 Penser Future Penser Future: Patientrekrytering i fokus - Abliva Pressreleaser Visa Stäng
2023-08-18 Abliva Abliva AB Delårsrapport januari-juni 2023 Rapporter Ladda ner | Visa Stäng
2023-08-18 Abliva Abliva AB Interim Report January – June 2023 Rapporter Ladda ner | Visa Stäng
2023-06-30 Abliva BioStock: First patient dosed in Abliva's Falcon study Pressreleaser Visa Stäng
2023-06-30 Abliva BioStock: Första patienten doserad i Ablivas Falcon-studie Pressreleaser Visa Stäng
2023-06-30 Abliva BioStock: Första patienten doserad i Ablivas Falcon-studie Pressreleaser Visa Stäng
2023-06-30 Abliva BioStock: First patient dosed in Abliva's Falcon study Pressreleaser Visa Stäng
2023-06-29 Abliva Abliva presenterar på UMDF Mitochondrial Medicine 2023 Pressreleaser Ladda ner | Visa Stäng
2023-06-29 Abliva Abliva presents at UMDF Mitochondrial Medicine 2023 Pressreleaser Ladda ner | Visa Stäng
2023-06-28 Abliva Abliva announces first patient dosed in the FALCON study Pressreleaser Ladda ner | Visa Stäng
2023-06-28 Abliva Abliva meddelar att första patienten doserats i FALCON-studien Pressreleaser Ladda ner | Visa Stäng
2023-06-14 Abliva BioStock: Abliva's presence is felt at Euromit Pressreleaser Visa Stäng
2023-06-14 Abliva BioStock: Ablivas CMO om presentation på Euromit Pressreleaser Visa Stäng
2023-06-12 Abliva Abliva presents scientific data at international conference on mitochondrial medicine Pressreleaser Ladda ner | Visa Stäng
2023-06-12 Abliva Abliva presenterar vetenskapliga data vid internationell konferens inom mitokondriell medicin Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Penser Future Penser Future: Tidsplan för FALCON-studien intakt - Abliva Pressreleaser Visa Stäng
2023-05-24 Penser Future Penser Future: Interview with Abliva - Erik Penser Bank - May 24th 2023 Pressreleaser Visa Stäng
2023-05-23 Abliva Abliva AB Interim Report January – March 2023 Rapporter Ladda ner | Visa Stäng
2023-05-23 Abliva Abliva AB Delårsrapport januari-mars 2023 Rapporter Ladda ner | Visa Stäng
2023-05-05 Abliva Beslut vid årsstämma den 5 maj 2023 i Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Abliva Resolutions from Annual General Meeting in Abliva AB (publ) on May 5, 2023 Pressreleaser Ladda ner | Visa Stäng
2023-05-04 Abliva Ändring av valberedningens förslag till Ablivas årsstämma 2023 Pressreleaser Ladda ner | Visa Stäng
2023-05-04 Abliva Amendment of the Nomination Committee's proposal for Abliva’s Annual General Meeting in 2023 Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

23 May 2024 | Årsstämma 2023
23 May 2024 | Kvartalsrapport 2024-Q1
24 May 2024 | Årligutdelning
22 Aug 2024 | Kvartalsrapport 2024-Q2
21 Nov 2024 | Kvartalsrapport 2024-Q3
21 Feb 2025 | Bokslutskommuniké 2024